CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

metrics 2024

Shaping the Future of Oncology Research

Introduction

Cancer Epidemiology Biomarkers & Prevention is a premier journal published by the American Association for Cancer Research, dedicated to advancing the understanding of cancer epidemiology, biomarkers, and preventive strategies. With an impressive impact factor that places it in the Q1 quartile across three critical categories — Epidemiology, Medicine, and Oncology — the journal stands as a vital resource for researchers and healthcare professionals seeking to explore novel insights in cancer prevention and control. The journal's rigorous selection process ensures the high quality of published research, making it a trusted source for the latest findings and methodologies in the fight against cancer. Although it currently does not support open access, the journal's comprehensive articles, spanning from its inception in 1983 to the present, facilitate significant advancements in the field. Located in Philadelphia, PA, this journal not only serves as a platform for dissemination but also stimulates vital discussions among the oncology community, ensuring that significant translational research reaches its audience effectively.

Metrics 2024

SCIMAGO Journal Rank1.69
Journal Impact Factor3.70
Journal Impact Factor (5 years)4.20
H-Index215
Journal IF Without Self3.70
Eigen Factor0.02
Normal Eigen Factor3.65
Influence1.64
Immediacy Index1.00
Cited Half Life10.00
Citing Half Life7.20
JCI0.90
Total Documents7739
WOS Total Citations18822
SCIMAGO Total Citations106090
SCIMAGO SELF Citations6238
Scopus Journal Rank1.69
Cites / Document (2 Years)3.08
Cites / Document (3 Years)3.39
Cites / Document (4 Years)3.71

Metrics History

Rank 2024

Scopus

Epidemiology in Medicine
Rank #35/148
Percentile 76.35
Quartile Q1
Oncology in Medicine
Rank #111/404
Percentile 72.52
Quartile Q2

IF (Web Of Science)

ONCOLOGY
Rank 104/322
Percentile 67.90
Quartile Q2
PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Rank 72/403
Percentile 82.30
Quartile Q1

JCI (Web Of Science)

ONCOLOGY
Rank 91/322
Percentile 71.74
Quartile Q2
PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Rank 118/403
Percentile 70.72
Quartile Q2

Quartile History

Similar Journals

CANCER RESEARCH

Shaping the future of cancer research with excellence.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 0008-5472Frequency: 24 issues/year

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

JNCI-Journal of the National Cancer Institute

Driving excellence in cancer research since 1940.
Publisher: OXFORD UNIV PRESS INCISSN: 0027-8874Frequency: 12 issues/year

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL

Innovating Solutions for Nutrition-Driven Cancer Outcomes
Publisher: ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTDISSN: 0163-5581Frequency: 8 issues/year

NUTRITION AND CANCER - AN INTERNATIONAL JOURNAL, published by ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD, stands as a vital resource in the interconnected realms of nutrition and oncology. Since its inception, this journal has been at the forefront of disseminating cutting-edge research and innovative findings related to the impact of nutrition on cancer prevention, treatment, and survivorship. With an impressive track record spanning from 1978 to 2024, this quarterly publication is categorized within the third and second quartiles across multiple fields, including Cancer Research and Nutrition and Dietetics, signifying its importance in these disciplines. Researchers and practitioners alike can benefit from its comprehensive studies, rigorous reviews, and insightful commentary, all aimed at fostering evidence-based practices for improving patient outcomes. Although not open access, the journal ensures wide dissemination of critical research findings, contributing to the global conversation on the role of dietary factors in cancer epidemiology. By exploring the latest advancements, NUTRITION AND CANCER invites a diverse audience of scholars, clinicians, and students to engage with the dynamic interplay between nutrition and cancer.

BULLETIN DU CANCER

Pioneering discoveries in cancer treatment and diagnostics.
Publisher: ELSEVIER MASSON, CORP OFFISSN: 0007-4551Frequency: 12 issues/year

BULLETIN DU CANCER is a pivotal academic journal dedicated to the field of oncology, providing a platform for innovative research and insights into cancer treatment and diagnostics. Published by Elsevier Masson, Corp Off in France, this journal has been a part of the scientific community since 1966, and is committed to sharing critical findings that influence clinical practices and improve patient outcomes. Despite its recent rankings placing it in the Q4 category for Cancer Research and Q3 for Hematology and other related fields, BULLETIN DU CANCER remains essential for those interested in the latest developments in cancer biology and treatment methodologies. With an emphasis on both basic and clinical research, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to deepen their understanding in various dimensions of oncology. This journal is particularly relevant as it continues to spotlight emerging research trends and supports the global imperative to combat cancer more effectively.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Advancing the Frontiers of Cancer Research.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

Cancers

Fostering collaboration in the fight against cancer.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

Infectious Agents and Cancer

Unraveling the complex interplay of infectious agents and oncology.
Publisher: BMCISSN: 1750-9378Frequency: 1 issue/year

Infectious Agents and Cancer is a pivotal open access journal published by BMC, dedicated to advancing research at the intersection of infectious diseases and oncology. Since its inception in 2006, this journal has provided a platform for the exploration of the complex relationships between infectious agents and cancer development, aimed at researchers, healthcare professionals, and students alike. With a broad scope encompassing epidemiology and cancer research, the journal holds an impressive ranking in the Q3 quadrant for epidemiology, infectious diseases, and oncology in 2023, while also featuring in the Q4 category for cancer research. This distinguished journal not only contributes to the enrichment of scientific knowledge but also fosters collaborative efforts towards innovative solutions in the fight against cancer. Being part of the UK publishing landscape, the journal is accessible to a global audience, ensuring that vital research findings are disseminated widely to inform policy and practice in health sciences.

BRITISH JOURNAL OF CANCER

Transforming Cancer Care with Cutting-Edge Discoveries.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

CANCER SCIENCE

Exploring the forefront of cancer science and medicine.
Publisher: WILEYISSN: 1347-9032Frequency: 12 issues/year

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

Gynecologic Oncology

Advancing the Frontiers of Gynecologic Cancer Research
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0090-8258Frequency: 12 issues/year

Gynecologic Oncology, an esteemed journal published by Academic Press Inc Elsevier Science, stands at the forefront of research in the domains of Obstetrics and Gynecology and Oncology. With an exceptional track record dating from 1972 to 2024, this journal has established itself as a vital resource for scholars and practitioners alike, boasting a remarkable Q1 ranking in both fields as of 2023. Gynecologic Oncology not only ranks #13 out of 209 in Obstetrics and Gynecology and #72 out of 404 in Oncology but also operates within the top percentiles of academic influence, with a 94th percentile in Obstetrics and Gynecology and an 82nd percentile in Oncology on Scopus. Although the journal does not currently offer open access, it remains crucial for disseminating original research, reviews, and advances in the management and treatment of gynecological cancers. Researchers and health professionals will find this journal indispensable for staying informed on the latest advancements and breakthroughs in this vital area of medicine, fostering a deeper understanding and potentially transforming patient care practices.